Endosense, a Geneva, Switzerland-based medical technology company, secured an additional USD$4.3m (CHF4m) in Series C financing.
The backer was a new unnamed strategic industry partner.
This second closing brings the total in series C funds raised to USD44.6m (CHF 41.4m) the company having previously raised $40.3m (read here).
Founded in in 2003 and led by Jan Keltjens, president, chief executive officer and chairman, Endosense develops contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias.
Endosense will use the funds to further develop its pipeline, to roll-out the TactiCath® Quartz contact-force sensing ablation catheter in Europe with a new direct sales force, and its program to get access to the U.S. market.